American Scitech International

Quick facts

Phase 3 pipeline

• R-mabHDI and ABVD · Oncology
  R-mabHDI is a monoclonal antibody targeting histone deacetylase inhibition combined with ABVD chemotherapy to enhance anti-tumor immune response and cytotoxicity in lymphomas.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• American Scitech International portfolio CI brief
• American Scitech International pipeline updates RSS